Answers are grounded in this paper and cite their sources.
Hypothermic treatment, initiated within the first six hours of life, is currently the main treatment capable of reducing brain damage in newborns with asphyxia and moderate or severe hypoxic-ischaemic encephalopathy. However, it is not yet clear how the treatment alters the newborn’s metabolic profile, nor whether such changes might mask or mimic a metabolic disorder, leading to false positives or false negatives in screening for inherited metabolic disorders. The present study therefore assessed changes in the metabolites routinely analysed in the Italian neonatal screening programme. A comparative analysis was conducted between full-term newborns with asphyxia/ hypoxic-ischaemic encephalopathy who underwent hypothermic treatment and a control group, through tandem mass spectrometry analysis. Treatment resulted in a number of changes being observed, including a decrease in glutamate, an increase in glycine, a reduction in certain short- and long-chain carnitines, and an increase in lysophosphatidylcholines. These findings suggest that hypothermic treatment may significantly alter the metabolic profile of the newborns. Consequently, the findings of our research have indicated that it is recommended to take dried blood spot samples at the conclusion of hypothermic treatment, with the aim of reducing the risk that the treatment may affect the interpretation of screening for inherited metabolic disorders. However, further studies are required to ascertain the usefulness and necessity of incorporating this second test into newborn screening protocols.
No takes yet. Share an insight, caveat, or question.
Messina et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: